An Early Christmas presentation was brought to about 10,000 Australians suffering from crippled kidney disease.
The first drug that effectively cures the life-threatening genetic condition is listed on the Pharmaceutical Benefits Scheme from January 1 and saves patients $ 23,000 a year, the federal government announced on Sunday.
Autosomal dominant polycystic kidney disease (ADPKD) is a progressive and painful condition that needs cysts to grow and grow in kidneys, most likely to be diarrhea or to transplant up to 60 years.
Helen Coolican, a Sydney native, has been dreaming of a drug that could help her husband, ADPKD, in 2010.
"You could give her a few more years, it's a valuable time when you're a parent," he told AAP.
There is a 50% chance of passing a parent with a sick child, so it was heartwarming, but it is not surprising to find the fourth child who is inherited from ADPKD.
Ms Coolican, part of the Australian PKD Foundation's founding team, said: "This drug has hoped for no hope."
"This is the best Christmas presentation."
The 66-year-old son of Sidney's North Coast donated kidney to his wife, Michael, but died about nine months later.
"It would be a transplant and, unfortunately, there is pneumonia, one of the things that happens when it comes to immunosuppression."
Jinarc (tolvaptan), a medication that prevents the activity of a naturally occurring hormone that increases ADPKD patients and promotes cysts in the kidneys.
Although they do not treat patients, they slow down the development of their condition, giving them more time until diagnosis and transplant occurs.
There are many complications including disease, including hypertension, chronic and acute pain, and recurring urinary tract infections.
According to the PBS list, around 900 patients will pay $ 40.30 for each article or $ 6.50 for discounted patients.
The delay of the disease through treatment is a better quality of life for the workers and for the patients over the years.
Australian Associated Press